Global cancer research initiative by Love, Richard R
© 2010 Love, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2010:2 105–109
Cancer Management and Research
9514
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
105
 ExPERT OPiniOn
open access to scientific and medical research
Open Access Full Text Article
Global cancer research initiative
Richard R Love
The Ohio State University 
Comprehensive Cancer Center, 
Columbus, OH, USA
Correspondence: Richard R Love 
B402 Starling Loving Hall, 320 W  
Tenth Avenue, Columbus,  
OH 43210, USA 
Tel +1 614 293 2268 
Fax +1 614 293 7526 
Email richard.love@osumc.edu
Abstract: Cancer is an increasing problem for low- and middle-income countries undergoing 
an epidemiologic transition from dominantly acute communicable disease to more frequent 
chronic disease with increased public health successes in the former domain. Progress against 
cancer in high-income countries has been modest and has come at enormous expense. There 
are several well-conceived global policy and planning initiatives which, with adequate political 
will, can favorably impact the growing global cancer challenges. Most financial resources 
for  cancer,  however,  are  spent  on  diagnosis  and  management  of  patients  with  disease  in 
circumstances where specific knowledge about effective approaches is significantly limited, 
and the majority of interventions, other than surgery, are not cost-effective in resource-limited 
countries by global standards. In summary, how to intervene effectively on a global scale for 
the majority of citizens who develop cancer is poorly defined. In contrast to technology-transfer 
approaches, markedly increased clinical research activities are more likely to benefit cancer 
sufferers. In these contexts, a global cancer research initiative is proposed, and mechanisms for 
realizing such an effort are suggested.
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Background
Cancer is an increasing problem in low- and middle-income countries, with high 
mortality. Cancer kills more people in the world each year than AIDS, tuberculosis, 
and malaria combined, with cancer accounting for 7–8 million deaths (at least four 
million in low-income countries), AIDS in about two million deaths, tuberculosis in 
about 1.3 million deaths, and malaria in about 860,000 deaths.1,2 By 2020, the global 
annual cancer incidence burden will be 20 million (70% in low- and middle-income 
countries) and the annual death burden is expected to exceed 10 million.3 Each 
year an increasing proportion of the global cancer burden is occurring in low- and 
middle-income countries, and, because of their large populations, in the countries of 
Asia. The incidence rates are increasing, and mortality rates from most cancers remain 
high in many resource-poor countries.5 There are two general differences between 
higher- and lower-income countries. First, smoking-related cancers are increasing 
in low-income countries and decreasing in higher-income countries, and the burden 
of cancer in women is increasing worldwide. Second, the burden of infection-related 
cancers is much greater in low-income countries than in high-income countries (25% 
versus 6%, respectively).4,5
Progress against cancer in high-income countries has been modest and has come at 
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selected Western countries, including the US. These salutary 
trends are consequent to multiple factors, and have occurred 
mostly in groups with higher socioeconomic status. By 
the international standards suggested by the World Health 
Organization (WHO) Commission on Macroeconomics 
and Health,6 few systemic interventions for cancer are sig-
nificantly cost-effective. Although few proven public health 
approaches are available, several hold promise, and some 
preventive interventions will also have beneficial effects on 
other chronic diseases. For example, antitobacco efforts, 
which have been successful in high-income countries, can 
be modified and duplicated with expectations of success 
in less resource-rich settings. The availability of effective 
human papilloma virus vaccines holds promise for a major 
reduction in uterine cervical cancer rates. Reduced smoking is 
associated with cardiovascular and nonmalignant pulmonary 
disease benefits. In contrast, many specific cancers are of 
relatively low incidence, and therapeutic strategies developed 
in high-income countries are generally very costly.
What do we know  
and what can be done?
First, as suggested by a recent Institute of Medicine report,7 
better cancer control is possible in truly developing countries 
by appropriate country-specific planning and policies which 
follow on from already available knowledge.
National Cancer Control plans8,9 (as described by the 
WHO, 2002), and the recent WHO modular reports on 
Cancer Control: Knowledge into Action, WHO Guide to 
effective programs; Planning, Prevention, Early Detection, 
Treatment and Palliative Care (2007–2008). Tobacco 
control (following the “Framework Convention on Tobacco 
Control”), hepatitis B virus vaccination (working with the 
“Global Alliance for Vaccines and Immunization – GAVI”), 
human papilloma virus vaccination, diet and nutrition (WHO 
report, and Report of World Cancer Research Fund/
American Institute of Cancer Research, 2007), Centers 
of Excellence (International Atomic Energy Agency – 
Programme of Action for Cancer Therapy-PACT), palliative 
care/pain control strategies (as suggested by the WHO 
and International Narcotics Control Board), surveillance 
and monitoring (implementation as recommended by the 
WHO-stepwise approach to chronic disease risk factor 
surveillance: STEPS; and the Institute of Medicine report). 
Building on these international recommendations and 
resources requires leadership, political will, some level of 
country-specific financial resources, and rigorous evaluative 
and problem-solving approaches.
Second, emerging data indicate that transmissible/
infectious agents or nutritional components and excesses 
contribute to, or are responsible for, the majority of global 
malignancies, explain the very large differences in cancer 
incidence between different populations, and account for 
most cancer deaths worldwide.4,5,10 Stomach (Helicobacter 
pylori-associated), liver (hepatitis B-associated) and uterine/
cervical (human papilloma virus-associated) cancers account 
for the overwhelming majority of the 25% of cancer deaths 
currently occurring in low- and middle-income countries. 
The increasing data associating diet, physical inactivity, and 
obesity, and increased incidence of several cancers (breast, 
colorectal, and prostate) have led to the recommendations 
of the World Cancer Research Fund report.9 Despite 
these circumstances, research resources directed towards 
understanding and treating these causes are relatively limited 
in low- and middle-income countries. Specifically, the asso-
ciation between hepatitis B and liver cancer is long-known, 
and population-effective vaccination programs have been 
implemented in some countries (eg, Taiwan), but liver 
cancer still causes approximately 750,000 deaths annually, 
reflecting an absence of population vaccination coverage. 
For nutrition-related cancers, such as colorectal and prostate 
malignancies, the very low rates of these cancers in India, 
for example, offer important opportunities to investigate 
protective dietary factors. Globally, the number of etiologic 
or interventional studies targeted towards these infectious 
and dietary issues is disproportionally low in comparison 
with their emerging public health significance.
Third, with respect to cancer diagnosis and systemic 
treatments other than surgery, which in most countries 
consumes the vast majority of resources allocated to cancer, 
knowledge is limited regarding specific effective applications 
of almost exclusively Western population-derived informa-
tion in low- and middle-income countries. One critical area 
is early detection and screening. The incidences of many 
malignancies vary markedly between countries. Breast cancer 
incidence in high-income countries is five times greater than 
in many low-income countries.11 This situation alone makes 
the costs of breast cancer screening and its cost-effectiveness 
less attractive in a low-incidence, low-income country. 
Despite expectations that significant downstaging of disease 
at diagnosis and an associated decrease in case fatality should 
be associated with well-conducted screening, clinical breast 
examination, and cervical inspection with acetic acid, the 
first results of a rigorous Indian clinical trial testing these 
 interventions in 151,538 women after three rounds of screen-
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downstaging for cervical cancer, with a developing trend for 
improved case fatality, but limited evidence for downstaging 
of breast cancer and no   improvement in case fatality.12 The 
biology and treatment of cancer exhibit significant differences 
between populations because of genetic differences in tumors 
and hosts (which affect metabolism and thus the efficacy 
and toxicities of systemic treatments),13–15 and in other life-
style and environmental factors. Increasingly, treatments 
are being designed for specific subgroups of patients with 
genetically-defined tumor changes. To study these treatments 
requires casting a wide net to recruit adequate numbers of 
study subjects in a timely manner. Parenthetically, new 
evidence suggests that we cannot consider all high-quality 
technical surgical interventions to be equivalent because 
host factors at the time of surgery may be associated with 
long-term outcomes.16 We are only beginning to understand 
the complex interrelationships of mind and body involved 
in “sickness”, and the interactions of cultural and personal 
representations of illness. Additionally, medical interven-
tions of all kinds vary dramatically in their feasibility, with 
favorable and unfavorable effects depending on psychosocial 
and cultural circumstances, particularly poverty. Finally, 
Western experiences in quality-of-care improvements have 
highlighted the challenges of defining truly effective inter-
ventions. Improvements require changes to be made within 
complex systems, and unintended consequences often occur.17 
In these contexts, interventions for cancer beyond surgery in 
previously unresearched populations (ie, in any other than 
generally well-off Western Caucasian populations) must be 
considered of uncertain benefit, and a formative evaluation 
strategy for application of any intervention in new popula-
tions is the safest approach.
The current practice in low- and middle-income countries 
for wealthy people is that they are offered treatments which 
are essentially duplicative of perceived state-of-the-art 
care in high-income countries, with no attention paid to 
probable   biologic/genetic differences in tumors and hosts. 
Two examples from breast cancer illustrate the hazards of 
such “one-shoe-fits-all” technology transfer approaches. 
First, accumulating evidence suggests that there are different 
alleles of genes critical to the conversion of tamoxifen to its 
active metabolite, endoxifen. Among Asian populations the 
more prevalent gene forms lead to limited endoxifen levels 
and therefore likely limited benefits from this treatment.15,18 
Second, doxorubicin is an effective chemotherapeutic agent in 
breast cancer, but again variants in gene alleles are important 
in its metabolism, leading to greater individual patient 
exposure to cardiotoxic breakdown products. Emerging 
evidence indicates that the “bad genes” are more common 
among Chinese women, in whom permanent iatrogenic 
heart damage is much more frequent, which changes the 
risk-benefit calculations for use of this drug.15 Third, for the 
majority of individuals in low- and middle-income countries, 
cancer care is “catch-as-catch-can” and limited in many 
ways. It is difficult to support these last two statements with 
specific and rigorous quantitative data, but after 15 years 
of on-site visits and patient management discussions with 
physicians in Vietnam, Philippines, China, Bangladesh, and, 
less frequently, in several other Asian and African countries, 
it is probable that they are correct. Fourth, currently defined 
useful systemic interventions for cancer are generally only 
widely applied in wealthy countries. The WHO Commission 
on Macroeconomics and Health has suggested that the cut-off 
for cost-effective interventions should be that a country’s 
per capita annual income should gain a year of life.6 By this 
standard, only a few current systemic interventions for cancer 
are cost-effective in most countries.
Summary
Public health policies are well-defined for important aspects 
of cancer, but optimal strategies for carrying these out in 
individual countries are poorly described and evaluated. 
Research on a global scale regarding the likely transmis-
sible agents and nutritional causes for the majority of 
cancers and their management is limited. Diagnosis and 
treatment consume the overwhelming bulk of resources 
for cancer in any country. Rigorous evidence regarding 
screening for certain cancers, such as breast and cervical, 
is lacking in low-income countries. Effective (but often 
significantly toxic) strategies in selected (genetic) popula-
tions have been developed, but these are not cost-effective. 
For the majority of citizens worldwide, effective, nontoxic, 
culturally appropriate, and attainable care for cancer has not 
yet been defined.
Discussion
A common thread in addressing cancer more effectively 
throughout the world is the need for research. How to 
intervene effectively is rarely known. A major increase in 
all aspects of population-targeted clinical cancer research is 
required, ie, etiologic, preventive, early detection, diagnosis, 
treatment, palliative care, and behavioral–psychosocial. In 
many circumstances what is needed is research specific to 
local countries.
Viewed globally, the preponderance of current clinical 
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populations. There is a major growing basic science research 
effort in the East (Hong Kong, Korea, China) and South East 
Asia (Singapore), and there is promise of similar activity in 
Saudi Arabia.
In the US, most cancer research has been federally 
funded, but less than 2% of the US National Institutes of 
Health cancer-directed budget is allocated to foreign research 
and the overwhelming majority of this is to high-income 
countries, ie, 74 of 78 projects in 2005. The US National 
Cancer Institute has assisted extensively in training foreign 
basic science and clinical researchers, and in the develop-
ment of population cancer registries. There is no doubt that 
addressing cancer problems in low-income countries is more 
attainable when there are specific relevant data. Recently, 
pharmaceutical company funding and studies have dominated 
the overall clinical interventional research portfolio. These 
important contributions acknowledge the stark reality that 
there is little “public health” oncology research. In terms of 
purchasing dollars, research supported by the US federal 
government is shrinking.
Financial support for cancer research by nongovernmental 
organizations is growing, but is still modest compared with 
federal support, and tends also to be niched in specialized 
areas and not public health-directed. The truly international, 
population-based, health-directed cancer research portfolio 
is embarrassingly small.7 Beyond the relatively small, but 
usually well-targeted, efforts of the International Agency 
for Research on Cancer (IARC), organizations focusing on 
international (public health, broad population-benefiting) 
cancer research are small and few in number, and the Global 
Research Forum barely considers cancer. The IARC has 
contributed significantly and usefully to the development of 
better global cancer data, and meaningfully in developing 
public health early detection information, but has been 
resource-limited to follow up these efforts with interventional 
research. The biggest foundations funding health research 
are generally confining their attention to long-neglected 
communicable diseases.
Proposal
A global cancer research initiative should be launched to 
develop and facilitate significantly increased numbers of col-
laborative international research activities and to generate data 
of significant benefit to individuals with cancer worldwide, 
particularly to individuals living in countries with limited 
resources. An international partnership-  collaborative group 
comprising, eg, the US National Cancer Institute, IARC, and 
European and Asian organizations should be developed to 
formulate the major goals, vision, and mechanisms for this 
initiative, and to procure commitments for sustained financial 
resources to carry out the initiative in rapidly incremental 
steps. The financial support should come from federal and 
private sources.
A core staff for the initiative should be recruited 
and should craft a series of requests for proposals from 
region-specific planning and organization through to 
intervention. Also needed are specifications which target 
low- and middle-income countries, their locally defined 
priority target areas, and the full spectrum of clinical research 
areas and funding rules which call for matching funds from 
all country research partner applicants, with greater levels 
sought from high-income countries. Rigorous low- and 
middle-income country clinical research investigator 
and proposal development, capacity-building training, 
and partnership/team development programs should be 
developed under the auspices of organizations such as the 
American Association for Cancer Research and American 
Society of Clinical Oncology. The deficit at present lies in 
mentoring foreign investigators in proposal and research 
team development.
Conclusion
Economic development efforts over the last 50 years 
have been broadly criticized for their limited successes, 
noting that “planning” rather than “search and research” 
approaches have dominated.19 Much discussion and many 
activities around addressing the growing cancer burden 
globally, and the organization and presentations at large 
clinical meetings, have been characterized by similar 
planning-technology transfer “solutions”. However, when 
we look at the state-of-the art in what we know about 
effective interventions in cancer in terms of how these might 
impact the majority of global citizens, it is clear that a more 
vigorous research approach is indicated to help low- and 
middle-income countries develop rigorous data on helpful 
interventions. The task is great, but if we are to realize the 
promise of the Declaration of Human Rights, ie, that the 
fruits of medical science should benefit all mankind, then 
medical science must more specifically turn its focus to 
global clinical cancer research.
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